Overview

Efficacy and Safety of Insulin Aspart Versus Glibenclamide in Type 2 Diabetes

Status:
Terminated
Trial end date:
2006-04-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in Japan. This is a clinical trial to study the efficacy and safety of thrice daily Insulin Aspart compared to Glibenclamide in type 2 diabetic patients.
Phase:
Phase 3
Details
Lead Sponsor:
Novo Nordisk A/S
Treatments:
Glyburide
Insulin
Insulin Aspart
Insulin degludec, insulin aspart drug combination
Insulin, Globin Zinc
Insulin, Long-Acting